EHRLICH JASON
Known title: See RemarksCIK: 0001754049
Associated companies
Transaction History
| KOD | ▼ Sell | Open Market | 2,258 | $21K | 6/16/2023 | View on chart |
| KOD | ▲ Buy | Option Exercise | 5,494 | — | 6/15/2023 | View on chart |
| KOD | ▼ Sell | Open Market | 1,132 | $11K | 6/14/2023 | View on chart |
| KOD | ▲ Buy | Option Exercise | 2,900 | — | 6/11/2023 | View on chart |
| KOD | ▼ Sell | Open Market | 2,282 | $16K | 6/17/2022 | View on chart |
| KOD | ▲ Buy | Option Exercise | 5,494 | — | 6/15/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 1,205 | $9K | 6/15/2022 | View on chart |
| KOD | ▲ Buy | Option Exercise | 2,900 | — | 6/11/2022 | View on chart |
| KOD | ▲ Buy | Option Exercise | 6,950 | $72K | 1/20/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 2,416 | $154K | 1/20/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 2,995 | $195K | 1/20/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 533 | $35K | 1/20/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 198 | $13K | 1/20/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 808 | $51K | 1/20/2022 | View on chart |
| KOD | ▲ Buy | Option Exercise | 6,950 | $72K | 12/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 1,709 | $151K | 12/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 1,532 | $133K | 12/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 3,709 | $325K | 12/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 106 | $11K | 11/22/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 1,071 | $108K | 11/22/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 1,881 | $187K | 11/22/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 191 | $18K | 11/22/2021 | View on chart |
| KOD | ▲ Buy | Option Exercise | 6,950 | $72K | 11/22/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 3,701 | $365K | 11/22/2021 | View on chart |
| KOD | ▲ Buy | Option Exercise | 6,950 | $72K | 10/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 1,252 | $141K | 10/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 5,698 | $636K | 10/20/2021 | View on chart |
| KOD | ▲ Buy | Option Exercise | 6,950 | $72K | 9/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 6,098 | $608K | 9/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 503 | $51K | 9/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 349 | $35K | 9/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 23 | $2K | 8/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 542 | $49K | 8/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 3,193 | $292K | 8/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 2,278 | $211K | 8/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 510 | $45K | 8/20/2021 | View on chart |
| KOD | ▲ Buy | Option Exercise | 5,258 | $54K | 8/20/2021 | View on chart |
| KOD | ▼ Sell | Open Market | 404 | $36K | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data
HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data. HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.